
Astrazeneca (Nasdaq:Azn) and Daiichi Sankyo (OTCPK: DSNKY) He announced that Enhert, their mutually developed antibodies, reached the main goal in the trial of Phase 3 in certain patients with an early degree of breast cancer as treatment before surgery.
Quoting data on the heating from